ResMed Inc. (RMD) is a global health technology company focused on sleep and breathing health, developing cloud-connected medical devices, masks, and digital health solutions for conditions such as sleep apnea and chronic respiratory diseases, alongside software for residential and out-of-hospital care. Headquartered in San Diego, California, ResMed serves customers in more than 140 countries and has a market cap of around $33.1 billion.
The company is slated to announce its first-quarter fiscal year 2027 results on Thursday, Oct. 29, after the market closes. Ahead of the event, analysts expect RMD to report an adjusted EPS of $2.70, up 5.9% from $2.55 in the year-ago quarter. It has surpassed Wall Street’s bottom-line estimates in each of the last four quarters.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For fiscal 2027, analysts expect RMD to report a profit of $12.07 per share, representing an 8.1% increase from $11.17 per share in fiscal 2026. Furthermore, its EPS is expected to grow 8.6% year-over-year to $13.11 in fiscal 2028.
www.barchart.com Shares of ResMed have decreased 12.9% over the past 52 weeks, lagging behind both the S&P 500 Index’s ($SPX) 16.2% gain and the State Street Health Care Select Sector SPDR ETF’s (XLV) 22.2% return over the same period.
www.barchart.com ResMed shares have faced pressure in 2026 primarily due to concerns over slower near-term growth and increasing competitive risks. The pressure intensified in August after ResMed issued weaker-than-expected fiscal 2027 revenue guidance of $5.75 billion to $5.85 billion, partly reflecting a $75 million revenue headwind from a safety-related suspension of Astral ventilator sales.
Meanwhile, for the last reported quarter, that is in Q4 FY2026, ResMed’s revenue increased 9% year-over-year (YOY) to $1.5 billion, while non-GAAP EPS increased 16% to $2.95. For the full fiscal year ended June 30, ResMed reported revenue of $5.7 billion, up 10% YOY, and non-GAAP EPS rose 17% to $11.17.
Wall Street analysts are moderately optimistic about RMD’s stock, with a “Moderate Buy” rating overall. Among 21 analysts covering the stock, eight recommend “Strong Buy,” one suggests a “Moderate Buy,” 11 propose “Hold,” and one advises a “Strong Sell” rating. The mean price target for RMD is $238.80, implying just 1.5% upside from the current levels.
On the date of publication, Subhasree Kar did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.